VISEN Pharmaceuticals, a biopharmaceutical company, engages in the research, development, and commercialization of paradigm-shifting endocrine therapies in Hong Kong, Macau, Taiwan, and rest of China. Its lead product Lonapegsomatropin, which has completed Phase III pivotal trial, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. The company also develops TransCon CNP (navepegritide), which has completed Phase II clinical trial, a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia; and Palopegteriparatide, which is in Phase III pivotal trial, a once-daily parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism. It has strategic collaboration with the United Family Healthcare. The company was incorporated in 2018 and is headquartered in Suzhou, China.